The loss of CK5/6 expression in ECs (observed in slightly more than a half of the cases) was significantly associated with a higher FIGO stage, increased tumor cell proliferation assessed by Ki-67 expression, reduced β-catenin expression, MI as well as an unfavorable patient outcome (66% 5-year survival vs. 86% 5-year survival (preserved CK5/6 expression), p = 0.0001). The gene discussed is KRT5; the disease is neoplasm.